TEMIS, a provider of Text Analytics, has introduced its first edition of Luxid, its Information Intelligence solution, serving the global information needs of Life Sciences Corporations. Luxid for Life Sciences offers advanced features dedicated to the analysis of the relations between biological, medical, and chemical entities. It provides a set of navigation and discovery tools designed to enable scientists to evaluate the "druggability" of a target or to profile a chemical compound; Luxid for Life Sciences gathers multiple patent sources, extracts, and normalizes key metadata (assignees, patent series) together with relevant entities (genes, diseases, chemical compounds). It is designed to allow patent lawyers to speed up patent portfolios analysis to better evaluate freedom-to-operate opportunities around promising chemical compounds and also to detect early signals of possible patent infringement; and Luxid for Life Sciences helps Marketing and Safety departments monitor adverse event related risks. Luxid for Life Sciences automates adverse event detection, through the extraction of relevant links between drugs, treatments, and induced pathologies or symptoms. It provides a workflow of escalation rules to comply with pharmacovigilance regulatory obligations.
|